



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PRODUCT INFORMATION




PF-06648671

Item No. 41893

CAS Registry No.: 1587727-31-8
Formal Name: 2-[(1S)-1-[(2S,5R)-5-[4-chloro-5-fluoro-2-(trifluoromethyl)phenyl]tetrahydro-2-furanyl]ethyl]-3,4-dihydro-7-(4-methyl-1H-imidazol-1-yl)-2H-pyrido[1,2-a]pyrazine-1,6-dione

Synonym: GSM22
MF: C₂₅H₂₃ClF₄N₄O₃
FW: 538.9
Purity: ≥95%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

PF-06648671 is supplied as a solid. A stock solution may be made by dissolving the PF-06648671 in the solvent of choice, which should be purged with an inert gas. PF-06648671 is sparingly soluble (1-10 mg/ml) in DMSO and slightly soluble (0.1-1 mg/ml) in acetonitrile.

Description

PF-06648671 is a γ -secretase modulator.¹ It selectively inhibits the production of amyloid- β (1-42) (A β 42) in CHO cells expressing wild-type amyloid precursor protein (APP; IC₅₀ = 9.8 nM) over Notch cleavage to its signaling effector Notch intracellular domain (NICD; IC₅₀ = >15.8 μ M). PF-06648671 (10 and 40 mg/kg) decreases brain levels of A β 42 in rats. It also decreases cerebrospinal fluid (CSF) levels of A β 40 and A β 42 and increases levels of A β 38 and A β 39, without affecting total A β CSF levels, in dogs when administered at a dose of 20 mg/kg.

Reference

1. Pettersson, M., Johnson, D.S., Humphrey, J.M., *et al.* Discovery of clinical candidate PF-06648671: A potent γ -secretase modulator for the treatment of Alzheimer's disease. *J. Med. Chem.* **67**(12), 10248-10262 (2024).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 09/06/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM